In accordance with the principles for appointing a Nomination Committee, which were adopted at Vivesto AB’s (”Vivesto”) Annual General Meeting on 25 May 2022, it is hereby announced that the Nomination Committee for the 2023 Annual General Meeting has been appointed, based on the ownership structure as per 30 September 2022.
The Nomination Committee for the 2023 Annual General Meeting comprises the following members:
- Per Arwidsson, appointed by Arwidsro Investment AB,
- Anna Henricsson, appointed by Handelsbanken Fonder, and
- Peter Zonabend, Chairman of the Board of Vivesto.
Per Arwidsson has been appointed Chairman of the Nomination Committee.
Vivesto’s Annual General Meeting will be held on 25 May 2023.
Shareholders who wish to submit proposals to the Nomination Committee for the 2023 Annual General Meeting may send them by e-mail to firstname.lastname@example.org. In order for the Nomination Committee to be able to consider submitted proposals in a constructive manner, these should be submitted well in advance of the Annual General Meeting.
For more information:
Peter Zonabend, Chairman of the Board of Vivesto
Phone: 018-50 54 40
About Vivesto AB
Vivesto is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. It has a growing pipeline of clinical-stage assets targeting late-stage cancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancer patients through a partnership with Elevar Therapeutics, Inc. Development programs include Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxel micellar, in development for advanced prostate cancer. Vivesto has proprietary drug delivery technology designed to improve solubility, efficacy and safety. Vivesto’s shares are traded on Nasdaq Stockholm (VIVE). To find out more about Vivesto please visit www.vivesto.com.